{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is AbbVie, Inc. technically bullish or bearish?
As of October 31, 2025, AbbVie, Inc. shows a mildly bullish technical trend with mixed signals from MACD and KST indicators, while underperforming the S&P 500 recently but outperforming it year-to-date, suggesting a cautious outlook.
Is AbbVie, Inc. technically bullish or bearish?
As of October 31, 2025, AbbVie, Inc. shows a mildly bullish technical trend with mixed indicators, having underperformed the S&P 500 recently but outperformed it year-to-date, suggesting caution despite the overall positive outlook.
Is AbbVie, Inc. technically bullish or bearish?
As of October 31, 2025, AbbVie, Inc. shows a mildly bullish technical trend, supported by positive MACD and Bollinger Bands, despite mixed signals from KST and Dow Theory, while it has underperformed the S&P 500 recently but outperformed it year-to-date.
AbbVie Stock Soars to New 52-Week High of $244.81
AbbVie, Inc. has achieved a new 52-week high, reflecting a strong performance with a notable increase over the past year. The company, with a market capitalization of USD 377,734 million, features a P/E ratio of 23.00 and a high dividend yield, despite some concerning financial metrics.
AbbVie, Inc. Hits New 52-Week High of $232.35, Showcasing Strong Growth
AbbVie, Inc. has achieved a new 52-week high, reflecting strong performance with a notable increase over the past year. The company, with a market capitalization of approximately USD 377.73 billion, features a P/E ratio of 23.00 and a substantial dividend yield, despite challenges in return on equity and debt-equity ratio.
AbbVie Stock Soars to Day High with Strong Intraday Performance
AbbVie, Inc. has seen a notable increase in its stock performance today, contrasting with the modest rise of the S&P 500. Over the past week and month, AbbVie has outperformed the index significantly. However, concerns remain regarding its high debt burden and weak long-term fundamentals.
AbbVie, Inc. Hits New 52-Week High of $225.16, Showcasing Strong Performance
AbbVie, Inc. achieved a new 52-week high of USD 225.16 on September 22, 2025, reflecting a strong performance with a 30.58% increase over the past year. The company, with a market cap of approximately USD 377.73 billion, faces challenges with a negative return on equity despite its notable dividend yield.
AbbVie Reaches New 52-Week High of $223.49, Reflecting Strong Growth
AbbVie, Inc. has achieved a new 52-week high, reflecting strong performance with a notable increase over the past year. The company, with a market capitalization of USD 377.73 billion, features a P/E ratio of 23.00 and a high dividend yield, despite reporting a negative return on equity.
Is AbbVie, Inc. technically bullish or bearish?
As of September 11, 2025, AbbVie, Inc. has a bullish technical trend supported by strong indicators across multiple time frames, outperforming the S&P 500 with a 7.46% return over the past month and 24.92% year-to-date.
Is AbbVie, Inc. overvalued or undervalued?
As of July 31, 2025, AbbVie, Inc. is considered overvalued with a P/E ratio of 23 and an EV to EBITDA ratio of 15.67, despite a strong year-to-date return of 24.92%, as it has underperformed the S&P 500 over the past three years.
AbbVie, Inc. Hits New 52-Week High at USD 222.07
AbbVie, Inc. has achieved a new 52-week high of USD 222.07, reflecting a strong performance with a 30.23% increase over the past year. The company, with a market capitalization of USD 377,734 million, features a P/E ratio of 23.00 and a notable dividend yield of 150.59%.
Is AbbVie, Inc. overvalued or undervalued?
As of October 27, 2023, AbbVie, Inc. is considered very expensive and overvalued with a P/E ratio of 23, a Price to Book Value of 240.68, and an EV to EBIT of 23.05, which exceed industry averages and suggest its growth prospects do not justify its current price level compared to peers.
Is AbbVie, Inc. technically bullish or bearish?
As of May 29, 2025, AbbVie, Inc. is in a mildly bearish trend, indicated by bearish MACD and moving averages, despite a mildly bullish signal from Bollinger Bands on the monthly chart.
Who are in the management team of AbbVie, Inc.?
As of March 2022, AbbVie, Inc.'s management team includes Chairman and CEO Richard Gonzalez, Lead Independent Director Glenn Tilton, and independent directors Dr. Robert Alpern, Ms. Roxanne Austin, Mr. William Burnside, and Mr. Thomas Freyman.
What does AbbVie, Inc. do?
AbbVie, Inc. is a large-cap biopharmaceutical company focused on the discovery, development, and sale of pharmaceutical products, with recent net sales of $13.34 billion and a market cap of approximately $333.93 billion. Key financial metrics include a P/E ratio of 23.00 and a dividend yield of 251.41%.
How big is AbbVie, Inc.?
As of Jun 18, AbbVie, Inc. has a market capitalization of approximately $333.93 billion, with net sales of $57.37 billion and a net profit of $4.16 billion over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
